At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Post-Market Trading 11-01 18:24:52 EDT
27.63
-0.22
-0.79%
盘后27.63
+0.000.00%
16:02 EDT
High28.38
Low26.91
Vol432.98K
Open28.19
D1 Closing27.85
Amplitude5.26%
Mkt Cap1.31B
Tradable Cap690.21M
Total Shares47.24M
T/O11.93M
T/O Rate1.73%
Tradable Shares24.98M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.